TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24060350
Drug: Reduced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced standard treatment plus a Web‐based psychosocial intervention (Therapeutic Education System - TES)
Study: 20638338
Drug: Acupuncture (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (traditional Chinese medicine)
Study: 18300256
Drug: Docetaxel weekly
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel weekly
Study: 15844060
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod 5% cream (Aldara; 3M Pharmaceuticals)
Study: 11973192
Drug: Target-Controlled Infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-Controlled Infusion
Study: 10392063
Drug: 1.1% IPAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% IPAA (Nutrineal, Baxter Healthcare Ltd) administered once per day for 18 weeks
Study: 2663834
Drug: Haloperidol, 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol, 0.25 to 4.0 mg/day (M = 0.844) for 4 weeks
Study: 1095996
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no estrogen therapy)
Study: 30261995
Drug: tiotropium/olodaterol 5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium/olodaterol 5/5 μg
Study: 30261995
Drug: tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium 5 μg
Study: 31694094
Drug: olodaterol 5
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olodaterol 5 μg
Study: 26431648
Drug: Holistic nursing
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic nursing combined with conventional therapy (test group I)
Study: 26431648
Drug: Oxygen-driving and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-driving and atomized Mucosolvan inhalation combined with holistic nursing (test group II)
Study: 24103895
Drug: Live-attenuated recombinant
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine (rHPIV3cp45)
Study: 21576828
Drug: Beta-blockers (atenolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (atenolol, 25-50mg/day, n=60)
Study: 21576828
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel antagonists (benidipine, 4-8 mg/day, n=60)
Study: 18801626
Drug: Intensive support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive support programme for community pharmacies to send discontinuation letters to patients.
Study: 17397739
Drug: Zernike treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zernike treatment tables
Study: 17397739
Drug: Fourier treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourier treatment tables
Study: 14671236
Drug: Glucose/potassium/insulin (GKI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose/potassium/insulin (GKI) infusions
Study: 9399737
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol 0.1 mg/day
Study: 9399737
Drug: 17beta‐estradiol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 0.1 mg and medroxyprogesterone acetate 2.5 mg/day
Study: 7956276
Drug: N-acetylcysteine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (150 mg/kg IV over 15 mins, then 12.5 mg/hr continuous infusion for 90 mins)
Study: 3294946
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of 8‐methoxypsoralen
Study: 3294946
Drug: Crystalline formulation
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline formulation of 8‐methoxypsoralen
Study: 29479974
Drug: Nefopam (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (120 mg) with fentanyl (20 µg/kg)
Study: 27465597
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated bacterial vaccines (typhoid and enterotoxigenic Escherichia coli)
Study: 22837377
Drug: Active continuous
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active continuous positive airway pressure treatment
Study: 22837377
Drug: Sham continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham continuous positive airway pressure treatment
Study: 22837377
Drug: Active continuous
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active continuous positive airway pressure treatment (crossover phase)
Study: 18450845
Drug: Antenatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal steroids > 7 days before delivery (remote group)
Study: 18450845
Drug: Antenatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal steroids 1 to 7 days before delivery (ideal group)
Study: 18450845
Drug: Antenatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal steroids 8 to 14 days before delivery (remote group subgroup)
Study: 18450845
Drug: Antenatal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal steroids > 14 days before delivery (remote group subgroup)
Study: 2033414
Drug: Monthly pulses
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly pulses of vincristine-prednisone (VCR-PDN) during maintenance therapy
Study: 2033414
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with mercaptopurine (6MP) and methotrexate (MTX) alone
Study: 7343274
Drug: Endralazine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine (initial dose 2.5 mg three times daily, increased to a maximum of 50 mg daily)
Study: 28776930
Drug: Family-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused treatment for youth at high risk (FFT-HR), 12 sessions in 4 months of family psychoeducation and skills training.
Study: 28776930
Drug: Family-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused treatment for youth at high risk (FFT-HR)
Study: 26492776
Drug: Less lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less lipid-lowering therapy
Study: 22992964
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow anaesthesia (0.8 L min(‐1) air-oxygen-sevoflurane (1-3 MAC))
Study: 22992964
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow anaesthesia (6 L min‐1)
Study: 22992964
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow anaesthesia (0.8 L min(‐1)) in non-cancer patients
Study: 17466785
Drug: ACUSEAL patch
Normalized name: ADAPTER,ACCUSEAL C#0219-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACUSEAL patch
Study: 17466785
Drug: Finesse patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finesse patch
Study: 16401653
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pramipexole and modafinil
Study: 11044538
Drug: Mini-pill
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mini-pill
Study: 27899067
Drug: Hydroxyzine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (25 mg)
Study: 30375109
Drug: Higher dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose: paracetamol 15 mg/kg + ibuprofen 4.5 mg/kg
Study: 30375109
Drug: Lower dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose: paracetamol 12 mg/kg + ibuprofen 3.6 mg/kg
Study: 30375109
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of the fixed-dose combination
Study: 24752957
Drug: Levofloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (10 mg/kg, maximum 500 mg)
Study: 24752957
Drug: Rifampicin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (10 mg/kg, maximum 450 mg)
Study: 17610348
Drug: Both Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Metformin and Simvastatin
Study: 16282000
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (pharmacological or psychological)
Study: 12849425
Drug: Anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory drugs (including glucocorticoid therapy, hydroxychloroquine, NSAIDs)
Study: 10200132
Drug: Salmeterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (200 micrograms daily, b.i.d. for 3 weeks)
Study: 7779545
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (G1)
Study: 6117726
Drug: Ribavirin small-particle
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin small-particle aerosol treatment
Study: 30744452
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment arm (target DBP <70 mm Hg)
Study: 30744452
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (target DBP ≥70 mm Hg)
Study: 23899131
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide (3% solution)
Study: 10567780
Drug: Gemifloxacin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (320 mg once daily)
Study: 11474633
Drug: Trovafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (200 mg once daily)
Study: 3171225
Drug: Ceftriaxone iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone iv in single daily doses of 75 mg/kg for children and 3-4 g for adults for seven days
Study: 3171225
Drug: Chloramphenicol 60
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol 60 mg/kg a day orally or iv in four divided doses until defervescence and then 40 mg/kg a day to complete 14 days
Study: 28419027
Drug: Positive-belief treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive-belief treatment (inert capsule described as a potent supplement)
Study: 28419027
Drug: Negative-belief treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-belief treatment (inert capsule described as a potent supplement)
Study: 28419027
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (received neither instruction nor capsule)
Study: 28419027
Drug: Intention to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intention to use supplements (within positive-belief treatment)
Study: 26514221
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (2 g)
Study: 26514221
Drug: Intraarticular tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular tranexamic acid (2 g)
Study: 23306586
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity (HI) continuous renal replacement therapy (CRRT)
Study: 23306586
Drug: Lower intensity
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intensity (LI) continuous renal replacement therapy (CRRT)
Study: 16406123
Drug: Encouraged to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encouraged to drink 240 ml of clear liquid prior to discharge
Study: 12875940
Drug: Deferred hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred hormonal treatment
Study: 12875940
Drug: Immediate hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate hormonal treatment
Study: 12875940
Drug: Immediate vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate vs Deferred hormonal treatment
Study: 12751395
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (0.5 to 2.0 mL depending on age) during suctioning
Study: 12751395
Drug: No isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No isotonic sodium chloride solution during suctioning
Study: 2507548
Drug: Intravenous supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous supplementation of enteral calories, n = 16
Study: 892120
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide suspension
Study: 30663175
Drug: Acotiamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide (100 mg tid)
Study: 26394822
Drug: ADHD stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD stimulant medication
Study: 26394822
Drug: No ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ADHD stimulant medication
Study: 23712475
Drug: Surgical intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical intervention (anterior cervical decompression and fixation) followed by anti-tuberculous medications (16 patients)
Study: 23712475
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (anti-tuberculous medications only) (13 patients)
Study: 15551197
Drug: Blind-randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind-randomized treatment with Paroxetine (PAROX) and Amitriptyline (AMI)
Study: 11682575
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.5 pmol x kg(‐1) x min(‐1) from 30 to 180 minutes)
Study: 11682575
Drug: Control (glucose
Normalized name: INFINITY CONTROL (GLUCOSE) NORMAL CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (glucose and insulin alone infusion)
Study: 9502624
Drug: Saruplase (20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saruplase (20-mg bolus and 60-mg infusion over 60 min)
Study: 9502624
Drug: Streptokinase (1.5-MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1.5-MU infusion over 60 min)
Study: 8044938
Drug: Glibenclamide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (10 mg oral)
Study: 23013352
Drug: Curcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (80 mg/day)
Study: 19093729
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid (ALA) 600 mg
Study: 18020969
Drug: B-vitamin supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplementation (2.5 mg folate, 0.5 mg vitamin B(12), 25 mg vitamin B(6))
Study: 18020969
Drug: B-vitamin supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplementation in hyperhomocysteinemic subjects (HCY>15 mumol/L, n=8)
Study: 9466103
Drug: Tramadol 20
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 20 mg
Study: 2460118
Drug: Digoxin (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (plasma drug concentration 1.3 to 2.0 nmol l‐1)
Study: 2460118
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg three times daily
Study: 22864946
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg D-amphetamine
Study: 22864946
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg D-amphetamine
Study: 21471971
Drug: Amlodipine complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine complex (5 mg amlodipine and 25 mg hydrochlorothiazide) administered at bedtime (2200 hours)
Study: 21471971
Drug: Amlodipine complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine complex (5 mg amlodipine and 25 mg hydrochlorothiazide) administered in the morning (0800 hours)
Study: 17428399
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy for house dust mite
Study: 17428399
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy for pollen
Study: 27382674
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacotherapy)
Study: 26994516
Drug: Sarolaner (Simparica™)
Normalized name: sarolaner Chewable Tablet [Simparica]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarolaner (Simparica™) administered at a minimum dosage of 2.0 mg/kg (range 2-4 mg/kg) on Days 0, 30, and 60
Study: 26994516
Drug: Spinosad (Comfortis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinosad (Comfortis® Chewable Tablets) as positive control
Study: 26994516
Drug: Sarolaner (Simparica™)
Normalized name: sarolaner Chewable Tablet [Simparica]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarolaner (Simparica™) administered at a minimum dosage of 2.0 mg/kg (range 2-4 mg/kg)
Study: 24829414
Drug: TLR agonists
Normalized name: TLR-AD1
DrugBank: TLR-AD1 (DB18241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR agonists (such as LPS)
Study: 20221707
Drug: Iomeron 400
Normalized name: Iomeron 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeron 400 (400 mg I/ml)
Study: 20221707
Drug: Iopamidol 300
Normalized name: iopamidol 300 mg iodine/mL (61 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 300 (300 mg I/ml)
Study: 1374724
Drug: Intraperitoneal 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal 5-fluorouracil (5-FU) administered as adjuvant treatment following liver resection (7 patients)
Study: 1374724
Drug: Intraperitoneal 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal 5-fluorouracil (5-FU) administered as palliative chemotherapy (13 patients)
Study: 6375873
Drug: Effervescent metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent metoclopramide and aspirin (Migravess) 650 mg and 10 mg
Study: 6375873
Drug: Effervescent aspirin
Normalized name: aspirin Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent aspirin 650 mg (Alka-Seltzer)
Study: 6375873
Drug: Effervescent metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent metoclopramide and aspirin (Migravess)
Study: 6375873
Drug: Effervescent metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent metoclopramide and aspirin (Migravess) vs Effervescent aspirin
Study: 31686981
Drug: Blood lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood lipid indicators (BLIs) correlated to insulin resistance (IR).
Study: 31686981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of indicators with diagnostic value for IR.
Study: 29888275
Drug: Azilsartan (Azil)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (Azil) as add-on treatment with Methotrexate (MTX) for 90 days
Study: 22035805
Drug: XEN402 (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN402 (400mg twice daily)
Study: 20705157
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg DRSP/30 mcg EE (Yasmin)
Study: 20705157
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg CMA/30 mcg EE (Belara)
Study: 20705157
Drug: 75 mcg
Normalized name: Levo-T 75 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mcg GSD/30 mcg EE (Minulet)
Study: 20705157
Drug: 150 mcg
Normalized name: kelp 150 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mcg DSG/30 mcg EE (Practil 21)
Study: 17400976
Drug: Immediate‐release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate‐release oxycodone 5 mg and acetaminophen 325 mg (Percocet‐5) four times daily
Study: 17400976
Drug: Controlled‐release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled‐release oxycodone 10 mg (OxyContin) every 12 hr and placebo twice daily
Study: 7880708
Drug: 51W89 (incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51W89 (incremental doses of 94 (19) micrograms kg-1)
Study: 1920787
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of buprenorphine at 0.2 mg.24 hr‐1
Study: 1920787
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of pethidine at 50 mg.hr‐1
Study: 6811447
Drug: procetofen (300‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: procetofen (300‐600 mg daily) for 6 months
Study: 30667285
Drug: Culturally Adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Adapted Treatment (CAT)
Study: 30667285
Drug: Standard Evidence-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Evidence-Based Treatment (EBT)
Study: 22915624
Drug: Intravenous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous abatacept (∼10 mg/kg)
Study: 21505147
Drug: Metreleptin (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.08 mg·kg(‐1)·day(‐1) for 10 wk)